AACC Webinar | Kidney Biomarkers | Supported by Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
19700
post-template-default,single,single-post,postid-19700,single-format-standard,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

AACC Webinar: Kidney Biomarkers and Shrunken Pore Syndrome*

SPS: AACC webinar supported by Gentian

AACC Webinar: Kidney Biomarkers and Shrunken Pore Syndrome*

The Use of Biomarkers in Chronic Kidney Disease and the Novel Disorder Shrunken Pore Syndrome (SPS)*

*this webinar is supported by Gentian

This AACC webinar* with Anders Grubb (MD, PhD, Professor in Clinical Chemistry, Lund University) focuses on renal biomarkers. Dr. Grubb will discuss the pros and cons of cystatin C and creatinine as kidney markers, and also share his insight about the novel disorder Shrunken Pore Syndrome (SPS):

How SPS is diagnosed

The mortality of SPS

The most common death causes associated with SPS

Hypotheses concerning its pathophysiology and treatment

Free AACC webinar:

Kidney Biomarkers and Shrunken Pore Syndrome

1.0 ACCENT Credits

Kidney disorders

Kidney disorders are very common and represent a significant and growing clinical problem. Such disorders are usually diagnosed by identifying a decrease in estimated Glomerular Filtration Rate (eGFR) using a creatinine- or cystatin C-based estimating equation for GFR. Dr. Grubb will show how the best estimation is obtained by using the average value of a cystatin C-based and a creatinine-based GFR estimating equation.

AACC webinar about kidney markers

Shrunken Pore Syndrome: Short introduction

Shrunken Pore Syndrome (SPS) was defined in 2015. The syndrome is characterised by the glomerular filtration of 5-40 kDa molecules being selectively decreased compared to that of molecules <0.2 kDa, e.g. water and creatinine. The mortality is strongly increased in all investigated populations and increases progressively with a decrease in the eGFRcystatin C/eGFRcreatinine ratio used to identify the syndrome. The syndrome might also explain the superiority of eGFRcystatin C over eGFRcreatinine in identifying high-risk kidney patients.

References:

Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: ‘Shrunken pore syndrome’

Shrunken Pore Syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting

FREE AACC WEBINAR:

KIDNEY BIOMARKERS AND SHRUNKEN PORE SYNDROME

1.0 ACCENT CREDITS

Glomerular Filtration Rate (GFR)

The Glomerular Filtration Rate (GFR) is the volume of primary urine produced per unit of time, corresponding to the volume of plasma filtered during that same time. GFR can’t be measured in humans, because it is not feasible to measure the filtration flow in the 800,000 human glomeruli. Diagnosis must therefore rely on estimations of GFR. Many potential markers for GFR are available, but only creatinine and cystatin C have been extensively evaluated.

AACC webinar, kidney markers, novel syndrome

P-Cystatin C and P-Creatinine: recommended as markers of GFR

P-Cystatin C and P-Creatinine are recommended as markers of GFR by both “The international society of nephrology in the KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease” and by SBU (Swedish Council on Health Technology Assessment) in their recommendation of 2013 ”Methods to Estimate and Measure Renal Function (GFR)”.

The AACC webinar

The American Association for Clinical Chemistry (AACC) is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare.

This webinar will be released for viewing via playback link sent to your email on September 11, 2019 at 1:00PM EDT.

Please sign up through www.aacc.org.

SPEAKER

Anders Grubb, MD, PhD
Professor in Clinical Chemistry
Lund University, Sweden
anders.grubb@med.lu.se

AACC webinar supported by Gentian